Clinical trials: Mouth Disease
Breast Cancer, Cholangiocarcinoma
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
This is an open-label, multicenter, global Phase 2 basket study of entrectinib (RXDX-101) for the treatment of patients with solid tumors that harbor an NTRK1/2/3, ROS1, or ALK gene fusion.
- Conditions
- Breast Cancer, Cholangiocarcinoma, Colorectal Cancer, Head and Neck Neoplasms
- Trial name
- STARTRK-2 (NCT02568267)
- Testing
- Entrectinib
- Where
- 120 sites in United States, Australia and 14 more
- Volunteers
- 534 people
- Sponsor
- Hoffmann-La Roche
Malnutrition
Improving Nutritional Status With Oral Nutritional Supplement in Chinese Elderly
This is a single- country, interventional, double-arm study involving Chinese Elderly subjects.
- Trial name
- NCT02360722
- Testing
- Oral Nutritional Supplement, Nutritional Education
- Sponsor
- Abbott Nutrition
Diabetes Mellitus
Study Evaluating Single Doses of PPM-204 on the Electrical Pathways of the Heart
A study evaluating the safety of a high and low dose of PPM-204 on the electrical pathways of the heart.
- Trial name
- NCT00447629
- Testing
- PPM-204
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Acne Vulgaris
"A Comparative Clinical Evaluation of the Efficacy of Topical Adapalene, Benzoyl Peroxide Gel, Oral Lactobacillus Rhamnosus, D-chiro-inositol, Inulin Capsule, and Their Fixed Combination in Mild to Moderate Acne Vulgaris Patients."
The study aims to conduct a comparative clinical evaluation of the effectiveness of a fixed topical combination of adapalene with benzoyl peroxide in the form of a gel, a fixed combination of Lactobacillus rhamnosus…
- Trial name
- NCT05855629
- Testing
- Oral Lactobacillus Rhamnosus, D-chiro-inositol, Inulin Capsule, Topical Adapalene, Benzoyl Peroxide Gel
- Where
- Ukraine
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- Treatment and Diagnostic Center of Private Enterprise "Asklepiy"
Diabetes Mellitus, Type 2
A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Insulin Glargine Taken Daily With Insulin Aspart (COMBINE 3)
This study will compare the new medicine IcoSema, which is a combination of insulin icodec and semaglutide, taken once a week, to insulin glargine taken daily with insulin aspart in people with type 2 diabetes.The study will look…
- Trial name
- NCT05013229
- Testing
- IcoSema, Insulin glargine, insulin aspart
- Where
- 182 sites in United States, Czechia and 12 more
- Volunteers
- 679 people
- Sponsor
- Novo Nordisk A/S
Fallopian Tube Cancer, Ovarian Cancer
CP-547,632 in Treating Patients With Recurrent or Persistent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
RATIONALE: CP-547,632 may stop the growth of tumor cells by blocking the enzymes necessary for their growth and by stopping blood flow to the tumor.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00096239
- Testing
- CP-547,632
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Colitis, Ulcerative
A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis
The purpose of this study is to evaluate the effectiveness and safety of ozanimod (RPC1063) in achieving and maintaining clinical remission.
- Trial name
- NCT05076175
- Testing
- Ozanimod
- Where
- 91 sites in United States, Australia and 11 more
- Volunteers
- 120 people
- Sponsor
- Bristol-Myers Squibb
Bypass Complications
Sustained-release Morphine Pharmacokinetics in Roux-en-Y Gastric Bypass Subjects
The purpose of this study is to determine whether sustained release morphine pharmacokinetics parameters in patients undergone roux-en-y gastric bypass (RYGB) differ from subjects who did not.
- Trial name
- OBEMO2 (NCT02641301)
- Testing
- Sustained release morphine sulfate, 30 mg
- Where
- 2 sites in France
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Hopital Lariboisière
Benign Prostatic Hyperplasia, Anticoagulant Adverse Reaction
Stop or Ongoing Oral Anticoagulation in Patients Undergoing Pvp (SOAP)
Benign prostatic hyperplasia (BPH) is a very common pathology of the aging man with an incidence that rises from 40% in men aged 50 to 60 years to 90% in men over 80 years.
- Trial name
- SOAP (NCT03297281)
- Testing
- Maintenance of OAC in surgery of BPH by PVP., Discontinuation of OAC in surgery of BPH by PVP.
- Where
- France
- Volunteers
- 389 people
- Sponsor
- Clinique Pasteur
Pancreatic Cancer
Personalised Nutritional Care in Older Patients With Pancreatic Ductal Adenocarcinoma
NutriCa65-PDAC is a clinical study for patients aged 65 years or older with pancreatic ductal adenocarcinoma, a type of pancreatic cancer.
- Trial name
- NutriCa65-PDAC (NCT07821554)
- Testing
- Experimental: Personalised nutritional care delivered by a trained dietitian
- Where
- 5 sites in Denmark, Italy and 3 more
- Volunteers
- 250 people
- Sponsor
- Inna Chen, MD
Atrophy, Vaginal Diseases
A Clinical Study to Evaluate Ospemifene in the Treatment of Vulvar and Vaginal Atrophy in Postmenopausal Women
The purpose of this study is to determine whether ospemifene is more effective than placebo in the treatment of vulvar and vaginal atrophy (VVA) in postmenopausal women.
- Trial name
- NCT00276094
- Testing
- Ospemifene 30 mg, Ospemifene 60 mg, Nonhormonal vaginal lubricant
- Volunteers
- 826 people
- Sponsor
- Shionogi
Cholera (Disorder)
VAXCHORA Pediatric Study to Assess Safety and Immunogenicity
VAXCHORA (Cholera Vaccine, Live, Oral) is a vaccine indicated for active immunization against disease caused by Vibrio cholerae serogroup O1.
- Trial name
- NCT03220737
- Testing
- VAXCHORA (Cholera Vaccine, Live, Oral)
- Where
- 10 sites in United States
- Volunteers
- 550 people, healthy volunteers welcome
- Sponsor
- Bavarian Nordic
Gastrointestinal Diseases
Bioequivalence Study of Raperazole 20mg DR Tabs and PARIET® 20 mg DR Tabs Under Fed Conditions
This is an open-label, randomized, single dose, two-sequence, two-periods crossover study, separated by 7 days washout interval from the first Study Drug Administration.
- Trial name
- NCT02605395
- Testing
- IDIAZOLE 20mg DR tabs, PARIET 20 mg DR tabs
- Where
- Egypt
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Candidiasis, Oral
Evaluation of the Effect of Different Cleaning and Disinfection Procedures on the Involvement of Candida Species
Individuals may experience tooth loss as a result of trauma, periodontal destruction, lack of adequate bone support and clinically dental mobility.
- Trial name
- NCT03894839
- Testing
- glutaraldehyde disinfection and microwave application, Chlorhexidine gluconate disinfection and microwave application, Sodium hypochlorite disinfection and microwave application
- Where
- Turkey (Türkiye)
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Yuzuncu Yil University
Gingivitis
Propolis Containing Chewing Gum and Gingivitis
Propolis is a natural, non-toxic, sticky substance produced by honeybees that can kill bacteria, fungi, and larvae invading the beehive. It has been used in the treatment of infections and healing of wounds and burns for years.
- Trial name
- NCT06685419
- Testing
- Propolis containing gum
- Where
- Turkey (Türkiye)
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- naksaka
Gingival Recession
Chorion Membrane With Photobiostimulation ,Chorion Membrane & SCTG in Treating Isolated RT 2 Recession Defects
Gingival recession (GR) is defined as apical displacement of the gingival margin relative to the cemento-enamel junction, with resultant oral exposure of the root.
- Trial name
- NCT06433973
- Testing
- Test group 1 - CM+LLLT+VISTA, Test group 2 - CM+VISTA, Control group - SCTG+VISTA
- Where
- India
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Postgraduate Institute of Dental Sciences Rohtak
Sjogrens Syndrome
Nipocalimab in Moderate to Severe Sjogren's Disease
The purpose of this study is to evaluate the clinical efficacy and safety of nipocalimab in participants with moderate to severe Sjogren's disease (SjD).
- Trial name
- DAFFODIL (NCT06741969)
- Testing
- Nipocalimab, Standard of care treatment
- Where
- 254 sites in United States, Argentina and 26 more
- Volunteers
- 655 people
- Sponsor
- Janssen Research & Development, LLC
Pulmonary Alveolar Proteinosis, Mutation Ala393Thr of the MARS Gene
Administration of Methionine in Patients With Pulmonary Alveolar Proteinosis by Mutation of the MARS Gene.
The purpose of this study is to determine the safety and tolerance of an oral administration of methionine in the treatment of pulmonary alveolar proteinosis due to the double mutation Ala393Thr / Ser567Leu in the MARS gene.
- Conditions
- Pulmonary Alveolar Proteinosis, Mutation Ala393Thr of the MARS Gene, mutationSer567Leu of the MARS Gene
- Trial name
- MetPAP (NCT03887169)
- Testing
- Methionine, Vitamin B12, B9, B6, C supplementation, Methionine/homocysteine Dosage
- Where
- France
- Volunteers
- 3 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Epilepsy, Focal
A Study of Brivaracetam in Subjects With Partial Onset Seizures
This trial will evaluate the efficacy and safety of brivaracetam (at doses of 50 and 150 mg/day in twice a day administration) as add on therapy in subjects with focal epilepsy
- Trial name
- NCT00175929
- Testing
- Brivaracetam
- Where
- 56 sites in Belgium, Czechia and 7 more
- Volunteers
- 157 people
- Sponsor
- UCB Pharma
Surgical Operation, Edentulous Jaw
Multicentric Observational Study Confirming the Performance and Safety of the Axiom® BL X3 Implants
This Post-Market Clinical Follow-Up study aims to document the success and survival of the Axiom® BL X3 Implants up to 3 years after loading.
- Conditions
- Surgical Operation, Edentulous Jaw, Edentulous Mouth, Implant
- Trial name
- Prospective_X3 (NCT05768295)
- Testing
- Axiom BL X3
- Where
- 13 sites in France
- Volunteers
- 200 people
- Sponsor
- Anthogyr
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.